U. S. cancer deaths have been declining since the 1990s. What, then, is there to talk about other than the good news in cancer prevention and treatment? August authors consider the ethical questions that clinical successes give rise to: extreme prices for drugs of marginal benefit; drug shortages that compel physicians to decide who receives preferred treatment, persistence of suboptimal care; the allure of experimental therapy when approved drugs fail; the ambiguous state of “survivorship”; and advances in whole genome sequencing that can reveal incidental information that patients (or patients’ families) may not want to know.